Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain

Life Sciences

Volumn 79, Issue 24, 2006, Pages 2311-2319

  Inceoglu, Bora ^a   Jinks, Steven L ^b   Schmelzer, Kara R ^a   Waite, Troy ^a   Kim, In Hae ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arachidonic acid; EETs; Inflammation; Pain; Soluble epoxide hydrolase

Indexed keywords

ARACHIDONIC ACID; EPOXIDE; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; IK 950; LINOLEIC ACID; LIPID; LIPOPOLYSACCHARIDE; N CYCLOHEXYL N DODECANOIC ACID UREA; PROSTAGLANDIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HYPERALGESIA; HYPOTHESIS; INFLAMMATION; LIPID METABOLISM; MALE; MECHANICAL ALLODYNIA; METABOLITE; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION; THERMAL HYPERALGESIA;

ANALGESICS; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HEAT; HYPERALGESIA; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY;

RODENTIA;

EID: 33750529521     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.07.031     Document Type: Article

References (44)

1. Campbell W.B., Brady M.T., Rosolowsky L.J., and Falck J.R. Metabolism of arachidonic acid by rat adrenal glomerulosa cells: synthesis of hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids. Endocrinology 128 (1991) 2183-2194
2. Campbell W.B., Gebremedhin D., Pratt P.F., and Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circulation Research 78 (1996) 415-423
3. Carroll M.A., Balazy M., Margiotta P., Falck J.R., and McGiff J.C. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. Journal of Biological Chemistry 268 (1993) 12260-12266
4. Chen J., Capdevila J.H., Zeldin D.C., and Rosenberg R.L. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Molecular Pharmacology 55 (1999) 288-295
5. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
6. Coutaux A., Adam F., Willer J.C., and Le B.D. Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine 72 (2005) 359-371
7. Dirig D.M., Isakson P.C., and Yaksh T.L. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. Journal of Pharmaceutical and Experimental Therapeutics 285 (1998) 1031-1038
8. Fabien J., Dogne J.M., Pirotte B., and de Leval X. Recent development in the field of dual COX/5-LOX inhibitors. Mini Reviews in Medicinal Chemistry 4 (2004) 633-638
9. Fang X., Moore S.A., Stoll L.L., Rich G., Kaduce T.L., Weintraub N.L., and Spector A.A. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. American Journal of Physiology 275 (1998) H2113-H2121
10. Fang X., Weintraub N.L., Stoll L.L., and Spector A.A. Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells. Hypertension 34 (1999) 1242-1246
11. Fang X., Weintraub N.L., McCaw R.B., Hu S., Harmon S.D., Rice J.B., Hammock B.D., and Spector A.A. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. American Journal of Physiology 287 (2004) H2412-H2420
12. Ferreira S.H., Moncada S., and Vane J.R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biology 231 (1971) 237-239
13. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 (1999) 493-497
14. Fleming I., and Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47 (2006) 629-633
15. Hadgraft J., and Lane M.E. Skin permeation: the years of enlightenment. International Journal of Pharmaceutics 305 (2005) 2-12
16. Harder D.R., Campbell W.B., and Roman R.J. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. Journal of Vascular Research 32 (1995) 79-92
17. Hargreaves K., Dubner R., Brown F., Flores C., and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988) 77-88
18. + channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. European Journal of Pharmacology 230 (1993) 215-221
19. Kanaan S.A., Saade N.E., Haddad J.J., Abdelnoor A.M., Atweh S.F., Jabbur S.J., and Safieh-Garabedian B. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain. Pain 66 (1996) 373-379
20. Kim I., Morisseau C., Watanabe T., and Hammock B.D. Design, synthesis, and biological activity of 1,3-Disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. Journal of Medicinal Chemistry 47 (2004) 2110-2122
21. Kozak W., Kluger M.J., Kozak A., Wachulec M., and Dokladny K. Role of cytochrome P-450 in endogenous antipyresis. American Journal of Physiology 279 (2000) R455-R460
22. Kozak W., Aronoff D.M., Boutaud O., and Kozak A. 11,12-epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Experimental Biology and Medicine (Maywood) 228 (2003) 786-794
23. Lee H.C., Lu T., Weintraub N.L., VanRollins M., Spector A.A., and Shibata E.F. Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. Journal of Physiology 519 (1999) 153-168
24. Makita K., Takahashi K., Karara A., Jacobson H.R., Falck J.R., and Capdevila J.H. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. Journal of Clinical Investigation 94 (1994) 2414-2420
25. Moncada S., Ferreira S.H., and Vane J.R. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature 246 (1973) 217-219
26. Morisseau C., Goodrow M.H., Newman J.W., Wheelock C.E., Dowdy D.L., and Hammock B.D. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochemical Pharmacology 63 (2002) 1599-1608
27. Needleman P., Truk J., Jakschik B.A., Morrison A.R., and Lefkowith J.B. Arachidonic acid metabolism. Annual Review of Biochemistry 55 (1986) 69-102
28. Nilius B., Vriens J., Prenen J., Droogmans G., and Voets T. TRPV4 calcium entry channel: a paradigm for gating diversity. American Journal of Physiology 286 (2004) C195-C205
29. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., and Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
30. Oliver J., Brandes R.P., Kim I.H., Schweda F., Schmidt R., Hammock B.D., Busse R., and Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45 (2005) 759-765
31. Oliw E.H., Guengerich F.P., and Oates J.A. Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. Journal of Biological Chemistry 257 (1982) 3771-3781
32. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., and Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proceedings of the National Academy of Sciences 102 (2005) 2186-2191
33. Schmelzer K.R., Kubala L., Newman J.W., Kim I., Eiserich J.P., and Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proceedings of the National Academy of Sciences 102 (2005) 9772-9777
34. Spector A.A., Fang X., Snyder G.D., and Weintraub N.L. Epoxyeicosatrienoic acids (EpETrEs): metabolism and biochemical function. Progress in Lipid Research 43 (2004) 55-90
35. Spiecker M., and Liao J.K. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Archives of Biochemistry and Biophysics 433 (2005) 413-420
36. Vadivelu N., and Sinatra R. Recent advances in elucidating pain mechanisms. Current Opinion in Anaesthesiology 18 (2005) 540-547
37. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology 231 (1971) 232-235
38. Vriens J., Watanabe H., Janssens A., Droogmans G., Voets T., and Nilius B. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proceedings of the National Academy of Sciences 101 (2004) 396-401
39. 2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circulation Research 97 (2005) 908-915
40. Watanabe H., Vriens J., Prenen J., Droogmans G., Voets T., and Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424 (2003) 434-438
41. Yeomans D.C., and Proudfit H.K. Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence. Pain 68 (1996) 141-150
42. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L.R., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circulation Research 87 (2000) 992-998
43. Zeldin D.C. Epoxygenase pathways of arachidonic acid metabolism. Journal of Biological Chemistry 276 (2001) 36059-36062
44. Zeldin D.C., Kobayashi J., Falck J.R., Winder B.S., Hammock B.D., Snapper J.R., and Capdevila J.H. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. Journal of Biological Chemistry 268 (1993) 6402-6407